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ABSTRACT: Chronic wasting disease (CWD)
adversely affects both wild and captive cervid
populations. A vaccine to prevent CWD
would be a highly desirable tool to aid in
disease management. To this end, we tested
in mule deer a combination of CWD vaccines
consisting of cervid prion peptide sequences
168-VDQYNNQNTFVHDC-182 and 145-
NDYEDRYYRENMYRYPNQ-164 that had
previously been shown to delay onset of
clinical disease and increase survival in a
mouse-adapted scrapie model. Thirteen cap-
tive mule deer (Odocoileus hemionus) were
divided into vaccine (n57) and control groups
(n56), and given prime and boost vaccina-
tions intramuscularly 5 wk apart. Eight weeks
postprime (3 wk postboost), all animals were
challenged via natural exposure to an envi-
ronment contaminated with infective CWD
prions. Deer were monitored intermittently
for prion infection by rectal and tonsil
biopsies beginning 275 days postchallenge.
All vaccinates responded to both peptide
conjugates present in the combination vaccine
as measured by enzyme-linked immunosor-
bent assay. However, all deer eventually
became infected regardless of vaccine status.
Key words: Cervid, chronic wasting dis-
ease, mule deer, prion, vaccine.
Chronic wasting disease (CWD), caused
by infectious cervid prion (PrPCWD),
affects several North American species,
including mule deer (Odocoileus hemi-
onus; Williams and Young, 1980). In
western North America, the expansion of
CWD coincided with population declines
of up to 50% in some areas (Miller et al.,
2008b). The captive deer industry also has
been significantly impacted (Spraker et al.,
2009). Both wildlife managers and com-
mercial deer producers could benefit from
a vaccine that prevents PrPCWD infection.
A previous vaccine study involving prion
peptide sequences identified two conju-
gate sequences, peptides 4 and 6, that
induced a delay in clinical disease onset
and prolonged survivorship in mice chal-
lenged with Rocky Mountain Laboratory
mouse-adapted scrapie (Pilon et al., 2007).
Here we describe a study in which mule
deer were vaccinated with the cervid
forms of peptides 4 and 6 and challenged
via exposure to a PrPCWD-contaminated
environment. We assessed the combined
vaccines’ ability to prevent PrPCWD infec-
tion in this species.
Peptide 4 (168-VDQYNNQNTFV-
HDC-182) and peptide 6 (145- NDYE-
DRYYRENMYRYPNQ-164) were pre-
pared as described by Pilon et al. (2007)
with the exception of increased scale of
conjugation and supplier of peptide (Mid-
west Bio-tech, Inc., Fishers, Indiana,
USA). Peptides 4 and 6 were 85.7%
identical (100% similar) and 94.7% iden-
tical (100% similar) to peptides 4 and 6
respectively in the mouse study. Peptide 6
was synthesized with a C-terminal linker
containing a glycine and cysteine for
sulfhydryl-mediated conjugation to blue
carrier protein (BCP; Biosonda, Santiago,
Chile). Peptide 4 was conjugated using the
cysteine amino acid at the carboxyl
terminus of the peptide. Both peptides
were .90% pure. Next, 22 mmol of each
peptide was conjugated separately to BCP
694
using the linker reagent sulfosuccinimidyl
4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (Sulfo-SMCC, Pierce, Rock-
ford, Illinois, USA). Peptide conjugates
were dialyzed into 2 L phosphate-buffered
saline (PBS) overnight using 10K molec-
ular weight cutoff dialysis membranes.
Protein concentration was determined by
bicinchoninic acid assay and formulated
into an oil-in-water emulsion with mollusk
stabilizing buffer (MSB) (30 mM phos-
phate; 400 mM NaCl; 41 mM sucrose;
pH57.4) and an adjuvant (AdjuvacTM;
Miller et al., 2000). The final peptide
conjugate concentration was 1 mg/mL.
In November 2005, thirteen 6-month-
old mule deer were acquired from a
CWD-free research herd at Washington
State University, Pullman, Washington,
USA. Animals were transported to the
United States Department of Agriculture
(USDA) Animal and Plant Health Inspec-
tion Service (APHIS)/Animal Population
Health Institute, Wildlife Research Facil-
ity, Colorado State University, Fort Col-
lins, Colorado, USA.
In January, 2007 seven deer were vacci-
nated in each hip with 3 mL (1 mg/mL) of
each vaccine for a total of 6 mg via
intramuscular (IM) injection. A booster
was administered 5 wk postprime as de-
scribed above. Six control deer were inject-
ed as described above using MSB. Three
weeks postbooster animals were transferred
to the Colorado Division of Parks and
Wildlife (CDPW), Foothills Wildlife Re-
search Facility, Fort Collins, Colorado, for
natural challenge. Deer were placed in a
0.04-ha paddock that was contaminated with
PrPCWD from previous CWD studies con-
ducted on the premises (Miller et al., 2012).
The study protocol was approved by the
USDA APHIS National Wildlife Research
Center and the CDPW institutional animal
care and use committees (IACUC).
Prior to vaccination, EDTA whole blood
was collected for genetic testing as de-
scribed by Spraker et al. (2002). Serum
was collected for analysis by enzyme-
linked immunosorbent assay (ELISA)
before prime and booster, and at 3, 7, 9,
15, and 21 mo postchallenge. For the
ELISAs, peptides were conjugated to
maleic anhydride plates (Thermo Scientif-
ic, Rockford, Illinois, USA) following man-
ufacturer’s instructions at 12.5 mg/mL.
Plates were blocked with SeaBlock (1:10)
(Pierce). Serum was diluted in PBS and
incubated 2 hr at 37 C covered with
parafilm. Plates were washed twice with
200 ml PBS containing 0.05% v/v tween-20,
and incubated at 37 C for 1 hr with 200 mL
1:500 goat-antideer IgG horseradish per-
oxidase–conjugated antibody (Kirkegaard
and Perry Laboratories, Gaithersberg,
Maryland, USA) diluted 1:2000 in PBS.
Fifty microliters 3,39,5,59-tetramethylben-
zidine (Pierce) was added to wells, incu-
bated at 37 C for 5 min, and quenched with
13 mL of 2M H2SO4. Plates were read at
450 mm (Opsys plate reader, Dynex
Technologies, Chantilly, Virginia, USA).
Prior to prime vaccination, rectal biop-
sies were collected to determine CWD
status (Wolfe et al., 2007); all animals were
CWD free. At 9, 15, and 21 mo post-
challenge, rectal and tonsillar biopsies
(Wolfe et al., 2002) were collected under
sedation using ketamine hydrochloride
(KetasetH, Fort Dodge Animal Health,
Fort Dodge, Iowa, USA; 7 mg/kg IM) and
xylazine hydrochloride (AnaSedH, Lloyd,
Inc., Shenandoah, Iowa, USA; 0.7 mg/kg
IM). Lymphoid tissues were collected
from alternating tonsils and rectal lym-
phoid tissue collected from a new location
each time. Tissues were fixed in 10%
buffered formalin and prepared for histo-
logic examination and immunohistochem-
istry as described by Spraker et al. (2006,
2009). Positive animals were defined as
having positively staining follicles in rectal
or tonsil tissue.
As animals became CWD positive on
biopsy, they were anesthetized with tileta-
mine hydrochloride/zolazepam (TelazolH,
Fort Dodge Animal Health; 3–5 mg/kg IM)
and xylazine hydrochloride (2.5 to 3.3
mg/kg IM) and euthanized with pentobar-
bital solution (90–150 mg/kg intravenously
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[IV]) or potassium chloride (400–1000 mEq
IV). As the IACUC-determined study
endpoint was disease status, and for
humane reasons, we did not allow progres-
sion to clinical disease once we determined
an animal biopsy positive. Necropsy was
performed and tissues were collected for
histologic examination: parotid, mandibu-
lar, retropharyngeal, mesenteric, ileoceco-
colic, abomasal, ruminal, hepatic, popliteal,
prescapular, and internal iliac lymph nodes;
nictitans; palatine tonsil; laryngeal tonsil;
obex; brain; lung; heart; liver; kidney;
spleen; bone marrow; spinal cord; muscle;
Peyer’s patches; ovary; uterus; and cervix.
Genetic analysis indicated all animals
were wild type (SS) at codon 225.
Genotypic variation at codon 225 may
influence the progression of CWD in mule
deer. Deer expressing polymorphism SF
experience decreased disease progression
as compared to those expressing SS
(Jewell et al., 2005; Fox et al., 2006).
Because the deer were all SS, it is unlikely
that the study outcome was influenced by
genetic variation; however, the contribu-
tion of other genes and PrP-flanking
regions to disease susceptibility or resis-
tance is not completely understood and
these cannot be ruled out as factors in the
efficacy of the vaccine. We also do not
know how SF deer might have responded
to this vaccine.
Infection rates and cumulative propor-
tion infected over time were compared
between treatment groups using one-sided
Fisher exact test performed in WinPepi
(Abramson, 2011). Statistical priority was
placed on minimizing chance of type II
error in the face of small sample size.
Therefore, statistical significance was con-
sidered at P#0.1. By 21 mo postexposure
12 deer showed evidence of prion infec-
tion regardless of vaccine status (Table 1).
One control died 13 mo postexposure and
was negative. All lymphoid tissues and
sections of brain were positive for
PrPCWD. Significant differences in overall
infection rates and cumulative proportion
infected over time were not detected
between treatment groups (one-sided
Fisher exact P$0.32; Table 1).
Vaccinates produced an antibody re-
sponse to both peptide-conjugate vaccines
5 wk postprime vaccination (Fig. 1). The
vaccine containing peptide 6 appeared to
generate a stronger immune response;
however, the immune response was tran-
sient, as an immediate decrease in absor-
bance was seen 3 mo postchallenge and no
detectable signal observed after approxi-
mately 1 yr postboost (data not shown).
No apparent relationship between ELISA
absorbance and CWD detection was
observed, as animals with high and low
ELISA absorbance were CWD positive at
the first and last time points (Table 1;
Fig. 1).
Intramuscular administration of the two
peptide-BCP conjugate vaccines formulat-
ed in Adjuvac did not prevent develop-
ment of lesions associated with CWD in
TABLE 1. Results of vaccine efficacy trial for chronic wasting disease in mule deer (Odocoileus hemionus) in
Colorado, USA, 2007. Number of biopsy-positive mule deer over total sampled per group, their identification
numbers, and the cumulative proportion infected at each time point after exposure to a PrPCWD-
contaminated pen.
Time
postexposure (mos )
Vaccinates Controls
No. positive/
total sampled ID No.
Proportion
infected
No. positive/
total sampled ID No.
Proportion
infected
9 3/7 1NV, 2KY, 27 0.43 1/6 26 0.17
15 0/4 0.43 2/5a O, H 0.5a
21 4/4 1BI, 1BR,
1NE, 34
1.0 2/2 2BI, 22S 0.83a
a One control died 13 months postexposure and was negative at that time.
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mule deer naturally exposed to PrPCWD at
this dosage level. The amount of total
antigen delivered to the deer was approx-
imately 20 times lower relative to the
original mouse study and was chosen
based on our development of this vaccine
system (Miller et al., 1997, 2000, 2008a).
In previous studies, adequate antibody
responses and vaccine effect were pro-
duced with lower antigen loads in deer as
compared to rodents. Additionally, there is
concern regarding autoimmune reactions
with high self-antigen loads. At this dosing
level, our vaccine combination may not
have elicited a sufficient antibody re-
sponse needed to achieve clinical effect.
No clinical signs indicating autoimmune
reaction were observed, suggesting higher
antigen concentrations or increased dosing
may be used without adverse events.
The lack of vaccine protection we
observed may be due to inadequate
antigen load; however, route of vaccina-
tion, species–specific immunologic differ-
ences, method of disease challenge, or
combinations thereof cannot be ruled out.
Our findings emphasize the importance of
continuing the search for a vaccine
candidate using the target species model
in a natural challenge environment.
We acknowledge the following individ-
uals for their valuable time and assistance
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Sirochman, Karl Held, Mike Lavelle,
Justin Fischer, Seth Nienhauser, Ri-
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volunteers and seasonal assistants. This
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Science Fellow program and the Colorado
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